Post-transplant metabolic dysregulation: Insights and implications for kidney graft survival

doi:10.5527/wjn.v15.i2.118270

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

(29)

(25)

(0)

(22)

(367)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Jun 25, 2026; 15(2): 118270
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118270

Table 4 Causes of dyslipidemia in kidney transplant recipients: Risk factors, drug contributions, and potential benefits of newer therapies

Cause	Risk factors	Drug contributions	Potential benefits of newer therapies
Glucocorticoids	Obesity, diabetes	Cholesterol increase, VLDL increase, LDL receptor activity decrease	Statins, PCSK9 inhibitors for resistant dyslipidemia
CNIs	CsA > TAC	CsA → LDL increase, HDL decrease; TAC → better lipid profile	Switching CsA → TAC improves LDL/TG
mTOR inhibitors	Sirolimus, everolimus	TGs increase, LDL increase, lipoprotein lipase activity decrease	Early statin therapy. Ezetimibe adjunct
Other causes	Diabetes, hypothyroidism, obesity, alcohol	Lifestyle + comorbidities	Lifestyle modification + statins

VLDL: Very-low-density lipoprotein; LDL: Low-density lipoprotein; PCSK9: Proprotein convertase subtilisin-kexin type 9; CNIs: Calcineurin inhibitors; CsA: Cyclosporine; TAC: Tacrolimus; HDL: High-density; TGs: Triglycerides; mTOR: Mammalian target of rapamycin.

Full Size Table

Citation: Elahi T, Ahmed S, Mubarak M. Post-transplant metabolic dysregulation: Insights and implications for kidney graft survival. World J Nephrol 2026; 15(2): 118270
URL: https://www.wjgnet.com/2220-6124/full/v15/i2/118270.htm
DOI: https://dx.doi.org/10.5527/wjn.v15.i2.118270

Elahi T, Ahmed S, Mubarak M. Post-transplant metabolic dysregulation: Insights and implications for kidney graft survival. World J Nephrol 2026; 15(2): 118270 [PMID: 42395658 DOI: 10.5527/wjn.v15.i2.118270]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.